Thermo Fisher Scientific Inc. said it will spend $150 million to expand operations at three pharmaceutical manufacturing plants in Italy and the U.S.
Facilities in Monza and Ferentino, Italy, and Greenville, N.C., are part of the expansion, which is expected to be completed in two years. Thermo Fisher plans to devote extra capacity for sterile liquids, freeze-dried products and commercial manufacturing.
The Waltham, Mass.-based company also plans to equip each of the sites with aseptic filling lines and isolator technology in response to customer requests.
"These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise," Thermo Fisher's President of Pharma Services Michel Lagarde said in a March 18 release.